Longer, fuller lives with digital-first care and research

Problem Tech Solves

Tech Brief

Healthcare and life sciences face large challenges including a global lack of clinicians, ageing populations, rising costs of treatment and, until recently, a need to conduct in-person care and research. This can result in large workloads, sporadic patient contact and delays in diagnosis, treatment and research. Our disease-agnostic, highly configurable, and scaleable platform can connect with many devices and be used to power ‘Hospitals at Home’, Software as a Medical Device (SaMD) solutions and decentralized and hybrid clinical trials. Huma’s technology increases patient contact, delivers real-world data in a timely manner, and saves time and money whilst enabling clinicians and researchers to work with a wider pool of people, creating more equitable healthcare. Our platform allows clinicians to treat patients with a range of diseases remotely, monitoring them at home and allowing clinicians to prioritise their patients appropriately for clinical intervention and care. It is already used for cardiovascular disease, diabetes, COVID-19 and orthopaedic and elective cardiac surgery. Evidence shows COVID-19 virtual wards powered by Huma’s technology can almost double clinical capacity, reduce hospital admissions by over 30%, reduce hospital stays by nearly 40% and deliver up to four times lower mortality rates. In diabetes, early work with a healthcare consortium in London, UK has found that patients lost 4.1kg in weight and had an average reduction in average blood glucose levels (HbA1c) of 17 mmol/mol in HbA1c.

Tech Differentiators

We aren’t just experts in one disease or one aspect of healthcare or research, we do it all. Our technology is disease-agnostic, device-agnostic and modular, so we can meet the needs of patients, clinicians and researchers. Constant iteration, user testing and input from our clinical team, is how Huma’s platform achieves 94% patient adherence across all age demographics (18+ years) with 95% saying it is easy to use. Patient and clinical experience is central to our product design process and the usability and accessibility of the Huma platform are demonstrated by the fact that ~40% of users are aged 60-80 years old. Our modular platform allows us to adapt to the needs of our customers and users, and deliver rapidly at scale. During COVID-19 we deployed our ‘hospital at home’ technology across 100 clinics in Germany in a single day. We believe in collaboration and as a global company, we partner with leaders across healthcare, life sciences, research and technology worldwide. We recently announced a new partnership with AstraZeneca, purchasing their digital health platform AMAZE to become the pharmaceutical giant’s digital arm. As a partner we provide far more than technology services, offering novel tools and approaches to clinicians and researchers to collect better-quality data. This leads to improved regulatory and reimbursement decisions in research and improved patient outcomes in health care settings. Our internal R&D team have experience in developing digital biomarkers, measures and algorithms, as well as validating and translating them into products.


Some of the evidence generated using our technology, focusing on cardiac care and research, includes: - A 6-month, single-arm, study of 100 atrial fibrillation patients, led by the Stanford School of Medicine in collaboration with Bayer and Huma. Results published in npj digital medicine showed Huma’s technology supported rapid participant recruitment (94% in 12 days), high engagement (99% of all ECG and BP measurements were completed, along with 91% of televisits and 85% of surveys; 86% participants expressed willingness to continue for a 12-18-month-long trial), and patients with low baseline oral anticoagulation (OAC) increased their medication adherence from 85% to 96%. https://www.nature.com/articles/s41746-022-00622-9 - Peer-reviewed evidence shows our technology supported clinicians from Royal Brompton hospitals to identify at-risk cardiac surgery patients. Of the 525 patients using our app, 51 were flagged as deteriorating; of these, ~90% had their surgery brought forward. https://academic.oup.com/jamiaopen/article/4/3/ooab053/6338193 - A 12-week pilot project with two Welsh health boards assessed the proactive and safe management of 40 heart failure patients using Huma’s platform. Outcomes included: positive patient feedback (net promoter score: +88), 10% admission avoidance, 5% early discharge, 75% reduction in medication optimisation time and 19% fewer outpatient attendances over 6 months. A previous independent evaluation of using the Huma app in acute care found savings of £58-£92 per patient, depending on the implementing organisation. This project is undergoing further evaluation, by a Value-Based Healthcare team and we are optimistic that similar, if not greater, savings have been realised for this project.

Why Us